Phase 3 PRABITAS: Biweekly FTD/TPI Plus Bevacizumab Meets OS Non-Inferiority With Less Toxicity in Metastatic Colorectal Cancer

The phase 3 PRABITAS study showed that a biweekly FTD/TPI plus bevacizumab regimen was non-inferior to the conventional regimen for overall survival in metastatic colorectal cancer, with fewer hematologic adverse events. The study enrolled 970 patients with refractory mCRC; median OS was 11.3 months with the biweekly regimen versus 10.3 months with the conventional regimen (HR 0.93, 95% CI 0.80-1.08; non-inferiority P<0.0001), but superiority was not shown.